High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

Vladimir M. Moiseyenko,Svetlana A. Procenko,Evgeny V. Levchenko,Alexey S. Barchuk,Fedor V. Moiseyenko,Aglaya G. Iyevleva,Nathalia V. Mitiushkina,Alexandr V. Togo,Igor I. Semionov,Alexandr O. Ivantsov,Dmitry E. Matsko,Evgeny N. Imyanitov

High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

2010

Vladimir M. Moiseyenko
Svetlana A. Procenko
Evgeny V. Levchenko
Alexey S. Barchuk
Fedor V. Moiseyenko
Aglaya G. Iyevleva
Nathalia V. Mitiushkina
Alexandr V. Togo
Igor I. Semionov
Alexandr O. Ivantsov
Dmitry E. Matsko
Evgeny N. Imyanitov

Background: Several Asian studies demonstrated feasibility of front-line administration of gefitinib for the treatment of non-small cell lung carcinomas (NSCLCs) harboring intrageni

Keywords:

General surgery
Epidermal growth factor receptor
Gefitinib
Progression-free survival
Erlotinib
Tyrosine-kinase inhibitor
Lung
Cancer research
Oncology
Lung cancer
Medicine
Internal medicine
Adenocarcinoma
Cell
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations